Comparative Pharmacology
Head-to-head clinical analysis: BRYNOVIN versus PROBUPHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRYNOVIN versus PROBUPHINE.
BRYNOVIN vs PROBUPHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Adult: 150 mg orally twice daily.
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist